Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. director Tyler Sloat acquired 246 shares of Class A Common Stock through the settlement of fully vested restricted stock units on July 5, 2026. These RSUs were granted in lieu of quarterly cash retainers under the company’s Non-Employee Director Compensation Program.
Following this equity grant, Sloat directly holds 10,210 shares of Class A Common Stock. This is a routine, compensation-related award rather than an open-market stock purchase or sale.
Hinge Health, Inc. submitted a Form 144/A disclosure listing proposed resales of Class A shares by Insight Venture Partners X, L.P. The excerpt shows multiple sale dates in June 2026 with per‑trade share counts and gross proceeds reported.
The filing also notes a Series B preferred stock conversion before IPO dated 07/03/2018 and a separate figure of 4,485,644 tied to securities wired to a portfolio company on that date.
Hinge Health, Inc. Form 144 notice lists proposed sales of Class A common stock by Insight Venture Partners (Cayman) X, L.P. on multiple dates in June 2026. The excerpt shows individual sale entries with share counts and gross proceeds for each date, and a reference to 711,528 Series B Preferred (07/03/2018) wired to the portfolio company.
Hinge Health, Inc. affiliate submitted a notice reporting proposed sales of Class A common shares. The filings list multiple transactions in June 2026 by Insight Venture Partners (Cayman) X, L.P., showing individual sales and dollar amounts on specific dates. The report also references Series B preferred stock tied to a pre-IPO conversion.
Hinge Health, Inc. (HNGE) filing a Form 144 reporting proposed sales of Class A common stock by Insight Venture Partners (Cayman) X, L.P. The excerpt lists multiple sale notices in June 2026, including 732,444 shares on 06/29/2026 and 266,290 shares on 06/24/2026.
The filing itemizes individual transfers with dollar values wired for each trade; sale dates shown range from 06/16/2026 through 06/29/2026. The document also references Series B Preferred converted before IPO and a prior wired transfer dated 07/03/2018.
Hinge Health, Inc. filed a Notice of Proposed Sale on Form 144 reporting proposed dispositions of Class A shares by Insight Venture Partners (Cayman) X, L.P. The filing lists multiple sale dates in June 2026 and a largest single entry of 600,613 shares on 06/29/2026 with a reported proceeds figure of $49,750,937.00.
The excerpt shows earlier June 2026 trades by the same holder ranging from 26,856 to 218,362 shares on separate dates, with reported dollar amounts for each line. The filing records a prior conversion event dated 07/03/2018 (Series B Preferred conversion) and notes shares were wired to the portfolio company.
Hinge Health, Inc. Chief Financial Officer James Budge reported a routine tax-related share disposition. A total of 4,614 shares of Class A Common Stock were relinquished and cancelled to satisfy federal and state tax withholding from the vesting of restricted stock units, in an exempt transaction under Section 16b-3(e). Following this tax-withholding event, Budge directly holds 430,786 shares of Hinge Health Class A Common Stock.
Hinge Health, Inc. President James Pursley reported a small, exempt tax-withholding transaction involving 831 shares of Class A Common Stock. These shares were relinquished and cancelled so the company could pay his federal and state tax obligations arising from the vesting of restricted stock units, as permitted under Section 16b-3(e). Following this non-market disposition, Pursley directly holds 740,066 shares of Class A Common Stock.
Hinge Health, Inc. director and Executive Chairman & Co‑Founder Gabriel M.I. Mecklenburg reported an exercise‑and‑sell transaction involving 83,334 shares of Class A Common Stock. He converted 83,334 shares of Class B Common Stock into the same number of Class A shares and then sold 83,334 Class A shares in multiple open‑market trades.
The sales, executed at prices ranging from about $82.38 to $86.58 per share, were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 1, 2025. After these transactions, Mecklenburg continues to hold significant exposure through direct Class B holdings and indirect interests via a family trust and a GRAT that are convertible into Class A shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to a proposed sale of 50,000 Restricted Stock Units of common stock, dated 05/21/2025. The filing also lists recent 10b5-1 sales by Gabriel Mecklenburg: examples include 06/01/2026 (83,334 shares for $5,018,130.15) and 06/05/2026 (50,000 shares for $3,276,840.00).